Duggal Shivangini, Sairam Shrilekha
Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA.
Cureus. 2025 Mar 24;17(3):e81108. doi: 10.7759/cureus.81108. eCollection 2025 Mar.
Autoimmune hepatitis (AIH) is a chronic liver disease characterized by histological, clinical, and laboratory findings, including elevated liver enzymes, immunoglobulin G (IgG), and autoantibodies. Belimumab, a monoclonal antibody targeting B-lymphocyte stimulator (BLyS), is primarily approved for systemic lupus erythematosus (SLE) but shows promise in improving liver function tests (LFTs) in patients with concurrent AIH and SLE. We present the case of a 24-year-old female diagnosed with AIH and SLE, whose elevated LFTs initially resisted standard azathioprine therapy. Upon switching to mycophenolate and belimumab, a notable reduction in LFTs was observed. This case highlights belimumab's potential as an adjunct therapy in AIH, especially in patients with overlapping autoimmune conditions, supporting its role in reducing systemic inflammation and autoimmune activity.
自身免疫性肝炎（AIH）是一种慢性肝病，其特征在于组织学、临床和实验室检查结果，包括肝酶、免疫球蛋白G（IgG）和自身抗体升高。贝利尤单抗是一种靶向B淋巴细胞刺激因子（BLyS）的单克隆抗体，主要获批用于治疗系统性红斑狼疮（SLE），但在改善合并AIH和SLE患者的肝功能检查（LFTs）方面显示出前景。我们报告一例24岁诊断为AIH和SLE的女性病例，其升高的LFTs最初对标准硫唑嘌呤治疗无反应。改用霉酚酸酯和贝利尤单抗后，观察到LFTs显著降低。该病例突出了贝利尤单抗作为AIH辅助治疗的潜力，尤其是在自身免疫性疾病重叠的患者中，支持其在减轻全身炎症和自身免疫活动方面的作用。
